In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.

@article{Lyles2012InVE,
  title={In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.},
  author={Sarah E Lyles and Rowan J Milner and Kelvin Y. Kow and Marc E Salute},
  journal={Veterinary and comparative oncology},
  year={2012},
  volume={10 3},
  pages={223-35}
}
This study evaluated the in vitro activity of masitinib mesylate against canine hemangiosarcoma (HSA) cell lines after treatment with increasing concentrations of masitinib mesylate (0.01-100 µM) for 24, 48 and 72 h. Results indicated that masitinib mesylate caused a dose- and time-dependent decrease in HSA cell proliferation. The 50% inhibitory concentration (IC(50) ) at 72 h for three HSA cell lines (DEN, Fitz and SB) was found to be 8.56, 9.41 and 10.65 µM, respectively. Further… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 11 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Hypertrophic osteopathy secondary to metastatic ovarian adenocarcinoma in a mare.

The Canadian veterinary journal = La revue veterinaire canadienne • 2016
View 4 Excerpts
Highly Influenced

Breed-Predispositions to Cancer in Pedigree Dogs

ISRN veterinary science • 2013
View 1 Excerpt

Tyrosine kinase inhibitor special issue.

Veterinary and comparative oncology • 2012

Similar Papers

Loading similar papers…